A review of phase II acute heart failure syndromes clinical trials.
Hospitalization for acute heart failure syndromes (AHFS) is a growing health care burden. Over 1 million hospitalizations occur annually, with a postdischarge mortality and rehospitalization rate of ~45% by 90 days and a financial cost greater than $20 billion. Attempts to improve outcomes through novel therapies have largely failed, suggesting new approaches are needed. We review phase II studies in AHFS to identify opportunities for future development programs.